Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 2Dermatologic 2CNS 2Tumor-Agnostic 1Plasma cell 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasm Metastasis 1

Interventions

Specimen Handling 18Biopsy 18pembrolizumab 12Magnetic Resonance Spectroscopy 12Paclitaxel 8X-Rays 5Bevacizumab 5trastuzumab deruxtecan 4durvalumab 4atezolizumab 4Standard of Care 4Fluorouracil 4Carboplatin 4Capecitabine 4Blood Specimen Collection 4nilotinib 3ipatasertib 3Taxes 3Radiotherapy 3Pemetrexed 3Oxaliplatin 3Nivolumab 3Leucovorin 3Exercise 3Cetuximab 3trametinib 2olaparib 2inavolisib 2dostarlimab 2copanlisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
omipalisib × Tumor-Agnostic × 30 days × Clear all
NCT02079740 2026-05-28

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡